News Only difference between LSD and synthetic psilocybin experience is duration, researchers say But there are some physiological differences between the two Natalia Buendia CalvilloMarch 2, 2022
Canada What amendments to Canada’s restricted drug program mean for patients and practitioners The new rules will facilitate safer access to substances like psilocybin, but many in need won't qualify, experts say Natalia Buendia CalvilloJanuary 11, 2022
Psychedelics Palliative care providers see psychedelic-assisted therapy as treatment option for existential distress: study Currently treatments are largely insufficient, so care providers encourage more research despite stigma Natalia Buendia CalvilloDecember 30, 2021
Business Numinus to start trading on TSX The firm will celebrate by ringing the opening bell at the stock exchange on Thursday Kathryn TindaleDecember 15, 2021
Cannabis Consuming cannabis while on psychedelics makes the experience stronger, researchers say Cannabis and 'classical' psychedelics could act on similar receptors Natalia Buendia CalvilloNovember 4, 2021
Canada Numinus set to open Canada’s first psychedelics neurology centre The Vancouver based firm is acquiring the Neurology Centre of Toronto in a cash and stock deal Natalia Buendia CalvilloJuly 7, 2021
News California Senate passes psychedelic decriminalization bill If Bill SB-519 passes, possession of psychedelics for personal would be decriminalized, but cultivation and sale is still outlawed Natalia Buendia CalvilloJune 2, 2021
Culture 3 key takeaways from the Womxn, Wellness and Cannabis Conference Industry leaders shared their perspectives in a welcoming space at the two-day online event Natalia Buendia CalvilloJune 2, 2021
News MindMed stock surges on Nasdaq listing approval After its stock jumped 66%, MindMed now rivals Compass Pathways as the world's most valuable psychedelic company Jared GnamApril 23, 2021
Industry update Attend next week’s psychedelics legalization debate Thursday, April 27, four experts including MAPS founder Rick Doblin and former US drug policy advisor Kevin Sabet debate the merits of psychedelic reform Nick LabaApril 16, 2021